These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 22179554)
1. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I. Wolf DA; Lenander AW; Nan Z; Braunlin EA; Podetz-Pedersen KM; Whitley CB; Gupta P; Low WC; McIvor RS Bone Marrow Transplant; 2012 Sep; 47(9):1235-40. PubMed ID: 22179554 [TBL] [Abstract][Full Text] [Related]
2. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease. Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583 [TBL] [Abstract][Full Text] [Related]
7. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610 [TBL] [Abstract][Full Text] [Related]
8. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model. do Nascimento CC; Aguiar O; Viana GM; D Almeida V Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559 [TBL] [Abstract][Full Text] [Related]
10. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Pievani A; Azario I; Antolini L; Shimada T; Patel P; Remoli C; Rambaldi B; Valsecchi MG; Riminucci M; Biondi A; Tomatsu S; Serafini M Blood; 2015 Mar; 125(10):1662-71. PubMed ID: 25298037 [TBL] [Abstract][Full Text] [Related]
11. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I. Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607 [TBL] [Abstract][Full Text] [Related]
12. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients. Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846 [TBL] [Abstract][Full Text] [Related]
13. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Zheng Y; Rozengurt N; Ryazantsev S; Kohn DB; Satake N; Neufeld EF Mol Genet Metab; 2003 Aug; 79(4):233-44. PubMed ID: 12948739 [TBL] [Abstract][Full Text] [Related]
14. Biomechanical and histological characterization of MPS I mice femurs. Ferreira NY; do Nascimento CC; Pereira VG; de Oliveira F; Medalha CC; da Silva VC; D'Almeida V Acta Histochem; 2021 Feb; 123(2):151678. PubMed ID: 33434858 [TBL] [Abstract][Full Text] [Related]
15. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Wang D; Zhang W; Kalfa TA; Grabowski G; Davies S; Malik P; Pan D Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19958-63. PubMed ID: 19903883 [TBL] [Abstract][Full Text] [Related]
16. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948 [TBL] [Abstract][Full Text] [Related]
17. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Ou L; Przybilla MJ; Koniar B; Whitley CB Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892 [TBL] [Abstract][Full Text] [Related]
18. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847 [TBL] [Abstract][Full Text] [Related]
19. Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the α-L-iduronidase gene in Hurler-Scheie syndrome. Ahmed A; Whitley CB; Cooksley R; Rudser K; Cagle S; Ali N; Delaney K; Yund B; Shapiro E Mol Genet Metab; 2014 Feb; 111(2):123-7. PubMed ID: 24368159 [TBL] [Abstract][Full Text] [Related]
20. Decreased performance in IDUA knockout mouse mimic limitations of joint function and locomotion in patients with Hurler syndrome. Kim C; Kwak MJ; Cho SY; Ko AR; Rheey J; Kwon JY; Chung Y; Jin DK Orphanet J Rare Dis; 2015 Sep; 10():121. PubMed ID: 26407983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]